Microencapsulated Sodium Butyrate Alleviates Immune Injury and Intestinal Problems Caused by Clostridium Perfringens through Gut Microbiota

Microencapsulated sodium butyrate (MS-SB) is an effective sodium butyrate additive which can reduce the release of sodium butyrate (SB) in the fore gastrointestinal tract. In this study, we assess the protective effects and mechanisms of MS-SB in ( )-challenged broilers. Broiler chickens were pre-treated with SB or MS-SB for 56 days and then challenged with three times. Our results indicate that the addition of MS-SB or SB before infection significantly decreased the thymus index ( < 0.05). Serum IgA, IgY, and IgM concentrations were significantly increased ( < 0.05), while pro-inflammatory IL-1β, IL-6, and TNF-α were significantly decreased ( < 0.05) under MS-SB or SB supplementation. Compared with SB, MS-SB presented a stronger performance, with higher IgA content, as well as a lower IL-1β level when normal or C. perfringens-challenged. While challenge significantly decreased the villus height ( < 0.05), MS-SB or SB administration significantly increased the villus height and villus height/crypt depth (V/C ratio) ( < 0.05). Varying degrees of SB or MS-SB increased the concentrations of volatile fatty acids (VFAs) during challenge, where MS-SB presented a stronger performance, as evidenced by the higher content of isovaleric acid and valeric acid. Microbial analysis demonstrated that both SB or MS-SB addition and infection increase variation in the microbiota community. The results also indicate that the proportions of , , , , , and were significantly higher in the MS-SB addition group while, at same time, infection increased the abundance of and . In summary, dietary supplementation with SB or MS-SB improves the immune status and morphology of intestinal villi, increases the production of VFAs, and modulates cecal microbiota in chickens challenged with . Moreover, MS-SB was more effective than SB with the same supplemental amount.